ProMed Pharma and DSM Biomedical recently announced a business development partnership focused on polymeric drug delivery. The collaboration combines ProMed’s micromolding and extrusion capabilities in conjunction with DSM’s biomedical polyurethanes, polyurethaneureas, and bioerodible amino acid-based polyesteramides. Get the full story on our sister site Medical Design & Outsourcing.
dsmbiomedical
Aerie expands drug-delivery tech deal with DSM Biomedical
Aerie Pharmaceuticals (NSDQ:AERI) said today that it expanded its drug-delivery R&D deal with DSM Biomedical. The two companies first joined forces in July last year to evaluate the sustained delivery of certain Aerie drugs using DSM’s polymer technology. Initially, the group was focused on developing drug-delivery tech for people with wet age-related macular degeneration and diabetic […]
